Review articles are how the peptide field digests its own velocity. They consolidate scattered preprints, name the inflection points, and tell investigators and investors which questions are now settled and which are not.
The 2026 review crop centers on a handful of themes. Cancer vaccines: the International Journal of Peptide Research and Therapeutics (May 2026) and the Garland et al. WIRES Nanomedicine review (May 2026) both map antigen selection, adjuvant choice, and delivery vehicle against pipeline activity. Antimicrobial peptides: Discover Oncology's May 2026 review extended AMP coverage to anticancer cytotoxicity and vaccine adjuvant uses. AI design: Chemical Communications (2026) and the Cell Biomaterials April 16 review chart the methods stack — discriminative mining, diffusion generation, RFpeptides — and the data that anchors each.
What to watch for in a peptide review: named programs and trials, sponsor identities, and the specific data gaps the authors flag. The good ones close with what won't be true in 18 months.
A Cell Biomaterials review published April 16 maps the AI-driven antibiotic-discovery landscape across two strategy families: mining (using discriminative models on genomic/proteomic sequence libraries) and generation (using diffusion and language models to design novel synthetic peptides exceeding nature's repertoire). Companion work flagged in the review includes the University of Pennsylvania AMP-Diffusion system, which produced tens of thousands of candidate peptides — 46 prioritized, three quarters bacterial-inhibitory, and two with in vivo efficacy matching approved antibiotics in mouse infection models.
A Chemical Communications (Royal Society of Chemistry) 2026 review on peptide-based drug design using generative AI synthesizes the methods landscape behind the wave of community competitions and pharmaceutical-industry de novo programs that landed in 2026. The review covers ProteoGPT and related protein-language-model architectures, AlphaFold3-based pose prediction, diffusion-model peptide structure generation, and the experimental-validation cycle that turns AI designs into bench-tested candidates. It frames the Tsinghua FRCBS NK2R Peptide Design Competition and the published ultra-long-acting GLP-1 receptor agonist de novo design work as proof-points that the AI-design stack has crossed the threshold from generative novelty to drug-discovery utility. The piece lands as the AI/peptide field tracks toward routine kilogram-scale syntheses (enlicitide PCSK9, others) and into Phase 1/2 candidates inside roughly 18 months from in silico design.
A 2026 Discover Oncology review (Springer Nature) consolidated the case for antimicrobial peptides (AMPs) as anticancer therapeutics across three mechanistic categories: direct cytotoxicity through cancer-cell-membrane disruption (the same cationic-amphipathic chemistry that makes AMPs antibacterial works on the negatively charged outer leaflet of cancer-cell membranes), intracellular targeting of mitochondria and DNA replication, and use as vaccine adjuvants that boost immune responses to neoantigens. The review joins the May 2026 International Journal of Peptide Research piece on peptide cancer vaccines, the Frontiers in Medicine April 2026 anticancer AMP review, and the Frontiers in Bioinformatics March 2026 computational AMP discovery review as part of the AMP-as-cancer-therapeutic literature wave. Clinical translation remains limited: AMP-based cancer drugs in development are mostly preclinical or Phase 1.
A review article published in the International Journal of Peptide Research and Therapeutics in May 2026 consolidates the current state of peptide-based cancer vaccines, covering antigen selection, adjuvant chemistry, and delivery platforms designed to address tumor evolution and immune escape. The review argues that despite persistent challenges around peptide stability and limited immunogenicity, the combination of nanomaterials and adjuvants has significantly enhanced immune response efficiency and targeted delivery — with applications in drug-resistant and metastatic cancers. The piece sits alongside two other May peptide vaccine reviews (WIRES Nanomedicine, Science Advances) and frames the ASCO 2026 peptide-oncology slate (BioVaxys MVP-S, BriaCell Bria-IMT, Evaxion EVX-01) as the clinical pipeline backing the review-paper momentum.
A WIRES Nanomedicine and Nanobiotechnology 2026 review by Garland and colleagues synthesizes the materials-science side of peptide-based cancer vaccine development: lipid nanoparticle delivery, dendrimer scaffolds, peptide self-assembly platforms, and adjuvant chemistry. The piece complements the broader review wave by focusing on delivery and formulation rather than antigen selection. Key themes: lipid-nanoparticle-encapsulated peptides show improved bioavailability and immune-cell uptake versus free peptides; self-assembling peptide hydrogels enable sustained antigen release at injection site; CpG and TLR agonist combinations remain the dominant adjuvant approach but with new variants emerging. The review positions peptide vaccines as catching up to mRNA cancer vaccines (BioNTech, Moderna programs) on delivery sophistication.